Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,889 INR | +0.12% | +5.91% | +16.27% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 48.95 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+16.27% | 3.51B | C- | ||
+29.68% | 681B | C+ | ||
+20.14% | 556B | B | ||
-4.35% | 361B | C+ | ||
+17.65% | 325B | B- | ||
+3.77% | 285B | C+ | ||
+14.32% | 235B | B+ | ||
+4.39% | 199B | B- | ||
-11.78% | 189B | A+ | ||
-3.79% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- JBCHEPHARM Stock
- Ratings J. B. Chemicals & Pharmaceuticals Limited